This article provides a comprehensive review of anti-VEGF agents in managing retinal vascular diseases, emphasizing India's unique healthcare challenges.
Key Points
This article aims to outline the evolution and current application of anti-VEGF therapy in retinal diseases, particularly in India.
Detailed historical analysis of anti-VEGF agents and their development.
Evaluation of pharmacological properties and clinical use in India.
Discussion on regulatory milestones and safety considerations.
Anti-VEGF therapy has significantly improved management of ocular neovascularization.
Restricted access due to economic factors and the role of biosimilars in improving treatment availability.
Emphasis on providing equitable retinal care solutions in diverse populations.